Last updated: 15:54
No Notes Added Yet
Aprameya Engineering Limited was founded in 2003 by two medical engineers, Mr. Saurabh Bhatt and Mr. Chetan Joshi, as a healthcare solution provider. The company specializes in turnkey project solutions for healthcare infrastructure such as Modular OT, ICU, NICU, CCU, and Prefabricated Projects. The company’s clientele includes various categories of government tenders from the Department of Medical & Health Services/Health and Family Welfare within Gujarat, Rajasthan, and Delhi. Aprameya Engineering Limited is engaged in the business of ...Read More
Aprameya Engineering Limited was founded in 2003 by two medical engineers, Mr. Saurabh Bhatt and Mr. Chetan Joshi, as a healthcare solution provider. The company specializes in turnkey project solutions for healthcare infrastructure such as Modular OT, ICU, NICU, CCU, and Prefabricated Projects. The company’s clientele includes various categories of government tenders from the Department of Medical & Health Services/Health and Family Welfare within Gujarat, Rajasthan, and Delhi. Aprameya Engineering Limited is engaged in the business of installation, setup, and maintenance of Intensive Care Units (ICU), Neonatal Intensive Care Units (NICU), Pediatric Intensive Care Units (PICU), Operation Theatre (OT), and prefabricated structure ward in hospitals and medical care centers on a turnkey basis. The management team at Aprameya Engineering Limited includes Jignesh Devubhai Suthar as the Chief Financial Officer, Sanjoly Jalan as the Company Secretary and Compliance Officer, and Ghanshyam Jha as the Business Development Manager. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹424 Cr.
Stock P/E 26.3
P/B 6.6
Current Price ₹223
Book Value ₹ 33.8
Face Value 10
52W High ₹360
Dividend Yield 0%
52W Low ₹ 108
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 200 | 78 | 65 | 136 | |
| Other Income | 0 | 0 | 0 | 1 | |
| Total Income | 200 | 78 | 66 | 136 | |
| Total Expenditure | 175 | 69 | 59 | 111 | |
| Operating Profit | 25 | 10 | 7 | 25 | |
| Interest | 1 | 2 | 2 | 3 | |
| Depreciation | 0 | 0 | 0 | 0 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 24 | 7 | 5 | 22 | |
| Provision for Tax | 8 | 2 | 1 | 6 | |
| Profit After Tax | 17 | 5 | 3 | 16 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 17 | 5 | 3 | 16 | |
| Adjusted Earnings Per Share | 11.9 | 3.8 | 2.5 | 8.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 109% | -12% | 0% | 0% |
| Operating Profit CAGR | 257% | 0% | 0% | 0% |
| PAT CAGR | 433% | -2% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 105% | NA% | NA% | NA% |
| ROE Average | 37% | 28% | 50% | 50% |
| ROCE Average | 31% | 23% | 39% | 39% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 15 | 20 | 23 | 64 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 13 | 12 | 12 | 6 |
| Other Non-Current Liabilities | 0 | 0 | -0 | -0 |
| Total Current Liabilities | 21 | 30 | 40 | 73 |
| Total Liabilities | 49 | 62 | 75 | 143 |
| Fixed Assets | 1 | 1 | 1 | 1 |
| Other Non-Current Assets | 4 | 5 | 4 | 6 |
| Total Current Assets | 43 | 56 | 70 | 136 |
| Total Assets | 49 | 62 | 75 | 143 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 2 | 0 | 0 |
| Cash Flow from Operating Activities | -0 | -13 | -10 | -11 |
| Cash Flow from Investing Activities | -3 | -2 | -1 | -0 |
| Cash Flow from Financing Activities | 5 | 13 | 11 | 11 |
| Net Cash Inflow / Outflow | 2 | -2 | 0 | -0 |
| Closing Cash & Cash Equivalent | 2 | 0 | 0 | 0 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 11.87 | 3.84 | 2.49 | 8.46 |
| CEPS(Rs) | 11.93 | 3.9 | 2.56 | 8.51 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 10.38 | 14.23 | 16.72 | 33.75 |
| Core EBITDA Margin(%) | 12.43 | 12.08 | 9.74 | 17.55 |
| EBIT Margin(%) | 12.52 | 12.24 | 10.31 | 17.91 |
| Pre Tax Margin(%) | 12.07 | 9.58 | 7.07 | 15.62 |
| PAT Margin (%) | 8.31 | 6.87 | 5.35 | 11.59 |
| Cash Profit Margin (%) | 8.35 | 7 | 5.49 | 11.66 |
| ROA(%) | 34.24 | 9.74 | 5.1 | 14.74 |
| ROE(%) | 114.38 | 31.17 | 16.11 | 36.77 |
| ROCE(%) | 88.78 | 24.87 | 11.79 | 31.11 |
| Receivable days | 48.7 | 159.98 | 279.32 | 232.58 |
| Inventory Days | 13.58 | 35.79 | 31.54 | 13.87 |
| Payable days | 102.38 | 636.83 | 167.51 | 2562.72 |
| PER(x) | 0 | 0 | 0 | 12.1 |
| Price/Book(x) | 0 | 0 | 0 | 3.03 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.09 | 0.54 | 0.81 | 1.65 |
| EV/Core EBITDA(x) | 0.71 | 4.34 | 7.73 | 8.96 |
| Net Sales Growth(%) | 0 | -60.94 | -16.59 | 108.26 |
| EBIT Growth(%) | 0 | -61.84 | -29.63 | 270.16 |
| PAT Growth(%) | 0 | -67.69 | -34.99 | 361.69 |
| EPS Growth(%) | 0 | -67.69 | -34.98 | 239.47 |
| Debt/Equity(x) | 0.94 | 1.44 | 1.8 | 0.47 |
| Current Ratio(x) | 2.06 | 1.87 | 1.77 | 1.86 |
| Quick Ratio(x) | 1.7 | 1.6 | 1.69 | 1.76 |
| Interest Cover(x) | 27.3 | 4.6 | 3.18 | 7.83 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.16 |
| # | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 73.53 | 73.53 | 73.53 | 74.05 |
| FII | 2.47 | 0.41 | 0 | 0 |
| DII | 3.24 | 0.72 | 0.77 | 0.7 |
| Public | 20.77 | 25.34 | 25.7 | 25.24 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 1.4 | 1.4 | 1.4 | 1.41 |
| FII | 0.05 | 0.01 | 0 | 0 |
| DII | 0.06 | 0.01 | 0.01 | 0.01 |
| Public | 0.4 | 0.48 | 0.49 | 0.48 |
| Others | 0 | 0 | 0 | 0 |
| Total | 1.9 | 1.9 | 1.9 | 1.9 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
